Keep in touch

Sub-Licensees

 

Aurobindo Pharma Limited

Sub-licences covering: tenofovir alafenamide (TAF), atazanavir (ATV), abacavir (ABC), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In September 2014, Aurobindo, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Aurobindo to manufacture the novel investigational medicines tenofovir alafenamide (TAF).

In July 2014, the MPP, Aurobindo and Bristol-Myers Squibb signed a new sublicencing agreement allowing it to manufacture atazanavir (ATV).

In June 2013, the MPP signed a sublicensing agreement with Aurobindo allowing it to manufacture abacavir for paediatric use in the 118 countries where 98.7% of children living with HIV reside. In October 2011, the MPP signed a sublicensing agreement with key generics manufacturer Aurobindo covering FTC, COBI, EVG, and the Quad. Aurobindo chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties.

top

Cipla

Sub-licence covering: tenefovir alafenamide (TAF), dolutegravir (DTG)

In September 2014, Cipla, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Cipla to manufacture the novel investigational medicines tenofovir alafenamide (TAF).

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Cipla allowing it to manufacture dolutegravir for paediatrics and adults use.

 

Desano

Sub-licence covering: tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat(COBI) and atazanavir (ATV)

In September 2014, the MPP, Desano and Gilead Sciences signed a sub-licensing agreement allowing Desano to produce a generic version of tenofovir alafenamide (TAF) and also of  tenofovir disoproxil fumarate (TDF), emtricitabine and cobicistat.

 

In May 2014, the MPP  and Bristol-Myers Squibb signed a sublicensing agreement with the active pharmaceutical ingredient manufacturer Desano allowing it to manufacture atazanavir (ATV).

top

Emcure Pharmaceuticals Limited

Sub-licences covering: tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], atazanavir (ATV)

In September 2014, Emcure, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Emcure to manufacture the novel investigational medicines tenofovir alafenamide (TAF). The recent agreement replace the former sub-licensing agreement dated February 2012.

 

In July 2014, the MPP and Bristol-Myers Squibb signed a new sublicensing and technology transfer agreement with Emcure allowing it to manufacture atazanavir (ATV).

top

Hetero Labs

Sub-licences covering: tenofovir alafenamide (TAF), dolutegravir (DTG), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In September 2014, Hetero Labs, the MPP and Gilead Sciences signed a sub-licensing agreement allowing Hetero Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF).

In August 2014, Hetero Labs, the MPP and ViiV Healthcare signed a sub-licensing agreement allowing Hetero to manufacture a generic version of dolutegravir (DTG) for both paediatrics and adults use.

In July 2012, the MPP signed a sublicensing agreement with leading generic ARV manufacturer Hetero. Hetero, like Aurobindo and Emcure, chose to take advantage of a key provision negotiated by the MPP so it can sell tenofovir to a larger number of countries and without paying royalties.

top

Laurus Labs

Sub-licences covering: tenofovir alafenamide (TAF), dolutegravir (DTG), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

In September 2014, Laurus Labs, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Laurus Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF). This recent agreement replace the former sub-licensing agreement dated September 2012.

In July 2014, the MPP and ViiV Healthcare signed a sub-licensing agreement with Laurus Labs allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

top

Micro Labs

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Micro Labs allowing it to manufacture dolutegravir for both adult and paediatric treatment.

top

Mylan

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Mylan allowing it to manufacture dolutegravir for both adult and paediatric use.

top

Shasun Pharma Solutions

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

On 25 February 2013, the MPP signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Shasun Pharma Solutions.

top

Shilpa Medicare

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In June 2013, the MPP, Shilpa Medicare and Gilead signed a sublicensing agreement allowing it to manufacture five key HIV medicines licensed to the MPP by Gilead Sciences in July 2011.

top

This page is also available in: French, Spanish